Results 11 to 20 of about 4,744 (194)

Implementation of DPYD testing in Bulgarian patients with cancer

Biotechnology & Biotechnological Equipment
Precision medicine has revolutionized cancer treatment, tailoring interventions based on individual genetic variations. Dihydropyrimidine dehydrogenase gene (DPYD) testing plays a crucial role in predicting severe fluoropyrimidine-related toxicities ...
Nelly Miteva-Marcheva, Hristo Ivanov, Elena Bangieva-Ivanova, Nikola Boyanov, Vili Stoyanova   +4 more
doaj   +3 more sources

Translating DPYD Genotype into DPD Phenotype: Using the DPYD Gene Activity Score [PDF]

Pharmacogenomics, 2015
The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a key role in the metabolism of fluoropyrimidines. DPD deficiency occurs in 4-5% of the population and is associated with severe fluoropyrimidine-related toxicity. Several SNPs in DPYD have been described that lead to absent or reduced enzyme activity, including DPYD*2A ...
Henricks, L.M., Lunenburg, C.A.T.C., Meulendijks, D., Gelderblom, H., Cats, A., Swen, J.J., Schellens, J.H.M., Guchelaar, H.J.   +7 more
openaire   +8 more sources

DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants. [PDF]

Genes (Basel)
Background/Objectives: The DPYD gene encodes the enzyme dihydropyrimidine dehydrogenase that metabolizes fluoropyrimidines. Genetic variants in DPYD have been associated with altered enzyme activity; therefore, accurate detection and interpretation is critical for individualized fluoropyrimidine therapy.
Salgado Garrido J, Alonso Llorente A, Teijido Hermida O, Beloqui Lizaso JJ, Grández Ladrón de Guevara R, Velasco EM, Vera García R, Valiente Martín A.   +7 more
europepmc   +4 more sources

Frequent intragenic rearrangements of DPYD in colorectal tumours [PDF]

The Pharmacogenomics Journal, 2014
Dihydropyrimidine dehydrogenase is a crucial enzyme for the degradation of 5-fluorouracil (5FU). DPYD, which encodes dihydropyrimidine dehydrogenase, is prone to acquire genomic rearrangements because of the presence of an intragenic fragile site FRA1E.
van Kuilenburg, A, Etienne-Grimaldi, M, Mahamat, A, Meijer, J, Laurent-Puig, P, Olschwang, S, Gaub, Marie-Pierre, Hennekam, R, Benchimol, D, Houry, S, Letoublon, C, Gilly, F, Pezet, D, Andre, T, Faucheron, J, Abderrahim-Ferkoune, A, Vijzelaar, R, Pradere, B, Milano, G   +18 more
openaire   +5 more sources

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece

Frontiers in Pharmacology, 2023
Introduction: Dihydropyrimidine dehydrogenase (DPD), encoded by DPYD gene, is the rate-limiting enzyme responsible for fluoropyrimidine (FP) catabolism.
Georgia Ragia, Georgia Ragia, Anthi Maslarinou, Anthi Maslarinou, Natalia Atzemian, Natalia Atzemian, Eirini Biziota, Triantafyllia Koukaki, Charalampia Ioannou, Ioanna Balgkouranidou, George Kolios, George Kolios, Stylianos Kakolyris, Nikolaos Xenidis, Kyriakos Amarantidis, Vangelis G. Manolopoulos, Vangelis G. Manolopoulos, Vangelis G. Manolopoulos   +17 more
doaj   +2 more sources

Nomenclature for human DPYD alleles

Pharmacogenetics, 1998
To standardize DPYD allele nomenclature and to conform with international human gene nomenclature guidelines, an alternative to the current arbitrary system is described. Based on recommendations for human genome nomenclature, we propose that each distinct allele be designed by DPYD followed by an asterisk and an Arabic numeral.
McLeod, H. L., Collie-Duguid, E. S., Vreken, P., Johnson, M. R., Wei, X., Sapone, A., Diasio, R. B., Fernandez-Salguero, P., van Kuilenberg, A. B., van Gennip, A. H., Gonzalez, F. J.   +10 more
openaire   +4 more sources

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress

Current Oncology, 2022
Background: 5-FU-based chemoradiotherapy (CRT) could be associated with severe treatment-related toxicities in patients harboring at-risk DPYD polymorphisms.
Antoine Desilets, William McCarvill, Francine Aubin, Houda Bahig, Olivier Ballivy, Danielle Charpentier, Édith Filion, Rahima Jamal, Louise Lambert, Phuc Felix Nguyen-Tan, Charles Vadnais, Xiaoduan Weng, Denis Soulières   +12 more
doaj   +2 more sources

Germline DPYD Variant Effect on Fluorouracil Toxicity [PDF]

, 2021
The fluoropyrimidines, 5-fluorouracil (5-FU) and capecitabine, are widely used for solid tumor treatment. They can cause early-onset, severe toxicities such as neutropenia, mucositis, colitis, emesis, and hand-foot syndrome. 5-FU and capecitabine are metabolized by the DPD enzyme, coded for by the DPYD gene.
Mills, Sarah
openaire   +2 more sources

Pharmacogenomics: DPYD and Prevention of Toxicity

Clinical Oncology
In 2020, the introduction of pre-emptive DPYD genotyping prior to the administration of systemic fluoropyrimidine-based chemotherapy represented one of the first widespread pharmacogenetic testing programmes to be applied nationally in the United Kingdom.
J. Keen, J.H. McDermott, E. Aguilar-Martinez, W.G. Newman   +3 more
openaire   +3 more sources

Balance of care activity after EMA recommendation for DPYD gene testing in Galicia [PDF]

Frontiers in Pharmacology
IntroductionSince April 2020, pretherapeutic screening for accessing the deficiency of the DPD enzyme by genotyping the dihydropyrimidine dehydrogenase gene (DPYD) is required by the European Medicine Agency (EMA) prior to the administration of ...
Almudena Gil-Rodríguez, Almudena Gil-Rodríguez, Sheila Recarey-Rama, Sheila Recarey-Rama, Ana Rodríguez-Viyuela, Ana Rodríguez-Viyuela, Francisco Barros, Francisco Barros, Angel Carracedo, Angel Carracedo, Angel Carracedo, Angel Carracedo, Olalla Maroñas, Olalla Maroñas, Olalla Maroñas, Olalla Maroñas   +15 more
doaj   +2 more sources